Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BHMT | Q93088 | 3/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962854 | 1.00 | S1PR2 (0.37) | S1PR2S1PR1ALDH1A1BHMTGPR84 | |
| Hydrochloric Acid SCHEMBL3959721 | 0.98 | S1PR2 (0.36) | S1PR2S1PR1ALDH1A1BHMTGPR84 | |
| Hydrochloric Acid SCHEMBL3959716 | 0.98 | S1PR2 (0.36) | S1PR2S1PR1ALDH1A1BHMTGPR84 | |
| Oxalic Acid SCHEMBL27613411 | 0.96 | S1PR2 (0.36) | S1PR2S1PR1ALDH1A1BHMTGPR84 | |
| SCHEMBL3967370 | 0.89 | S1PR2 (0.42) | S1PR2S1PR1ALDH1A1GPR84FFAR1 | |
| SCHEMBL3962194 | 0.89 | S1PR2 (0.42) | S1PR2S1PR1ALDH1A1GPR84FFAR1 | |
| SCHEMBL3961814 | 0.87 | S1PR2 (0.44) | S1PR2S1PR1ALDH1A1GPR84FFAR1 | |
| SCHEMBL3963195 | 0.87 | S1PR2 (0.44) | S1PR2S1PR1ALDH1A1GPR84FFAR1 | |
| SCHEMBL28754981 | 0.84 | S1PR2 (0.36) | S1PR2S1PR1ALDH1A1BHMTLMNA | |
| SCHEMBL3962591 | 0.84 | S1PR2 (0.36) | S1PR2S1PR1ALDH1A1BHMTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227872-A1 | PYRAZINE DERIVATIVES | KEMP MARK IAN | 2010-09-09 | — | — | US | disclosed |
| EP-1492761-B1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER LAMBERT CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090036487-A1 | Combinations | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-7419981-B2 | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor | PFIZER INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1536782-B1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | disclosed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
| EP-1670452-A2 | METHOD OF USE OF AMINOACIDS HAVING AFFINITY FOR THE A2D PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1536782-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005030184-A2 | THERAPEUTIC BETA AMINOACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050065176-A1 | Combinations | FIELD MARK JOHN (GB) | 2005-03-24 | — | — | US | disclosed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040157847-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-08-12 | — | — | US | disclosed |
| US-20040092522-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-05-13 | — | — | US | disclosed |
| WO-2004016259-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036487-A1 | Combinations | CHRNE, CHRND, CHRNG | S1PR2 914/4885S1PR1 1157/4885ALDH1A1 4325/4885 |
| US-20100227872-A1 | PYRAZINE DERIVATIVES | CYP3A5, TRPV5, TRPV1 | S1PR2 1439/4885S1PR1 1790/4885ALDH1A1 617/4885 |
| US-20040092522-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | S1PR2 593/4885S1PR1 1254/4885ALDH1A1 1358/4885 |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | S1PR2 3566/4885S1PR1 4618/4885ALDH1A1 2020/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | S1PR2 3395/4885S1PR1 4348/4885ALDH1A1 3683/4885 |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, SCN1A | S1PR2 3482/4885S1PR1 4491/4885ALDH1A1 2297/4885 |
| US-20050065176-A1 | Combinations | CHRNE, CHRND, CHRNG | S1PR2 914/4885S1PR1 1157/4885ALDH1A1 4325/4885 |
| US-20040157847-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | S1PR2 593/4885S1PR1 1254/4885ALDH1A1 1358/4885 |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | S1PR2 3566/4885S1PR1 4618/4885ALDH1A1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.